NewG Lab Pharma and Arije Yak Collaborate on Development of Two Over-the-Counter Drugs

Two Over-the-Counter Drugs: Rhinitis Treatment and Menstrual Pain Relievers

[Asia Economy Reporter Hyungsoo Park] Newgelab Pharma has completed the value chain from development to production and distribution just over three years after entering the bio business. It is accelerating the launch of improved new drugs and generic product lines. Newgelab Pharma plans to accelerate new drug development based on stable sales through the sales and distribution of pharmaceuticals developed by its subsidiaries.

Newgelab Pharma announced on the 28th that it is jointly developing two over-the-counter drugs for allergic rhinitis and menstrual pain with its subsidiary Arije Yak. Distribution and sales will begin in the second half of this year.

The drugs are developed in chewable tablet form that can be chewed or dissolved without water to enhance ease of administration. After completing the pharmaceutical product notification in the second half of this year through collaboration in formulation development, production will be handled by Arije Yak, which has KGMP (Korean Good Manufacturing Practice) certified facilities. Newgelab Pharma, which holds a pharmaceutical wholesale and retail license, will be responsible for distribution, creating a stable revenue base.

The number of patients treated for allergic rhinitis in Korea was estimated to be about 9 million in 2020. Seasonal allergic rhinitis is especially prevalent among children under 9 years old. The chewable tablet form, which is easy for children to take, targets the allergic rhinitis treatment market.

The female-specific painkiller (for menstrual pain) is also a drug targeting a specific gender, with high growth potential due to the high demand for painkillers among female consumers.

A Newgelab Pharma official said, "The two over-the-counter drugs currently under development can be immediately approved by the Ministry of Food and Drug Safety through notification according to the pharmaceutical standard manufacturing guidelines." He added, "Through close consultations with Arije Yak regarding formulation development and mass production, we will begin distribution and sales of these drugs in the second half of this year."

He continued, "Starting with the launch of these over-the-counter drugs, we plan to continuously release improved new drugs and generic product lines that enhance medication convenience and drug accessibility," adding, "Improved new drugs and generic pharmaceuticals will become a pillar of Newgelab Pharma's growth and an important foundation for future new drug development."

Earlier, on the 15th, Newgelab Pharma's subsidiary Newgen Therapeutics received approval from the Ministry of Food and Drug Safety for clinical phase 1 trials of the improved new drug for diabetes combination therapy, ‘NGL-101’. NGL-101 will also be produced by Arije Yak and sold by Newgelab Pharma in the future.

Newgelab Pharma acquired management rights of the pharmaceutical manufacturing specialist company Arije Yak in February last year. Arije Yak obtained KGMP certification in 2019 and holds licenses for 87 pharmaceutical product items.

This content was produced with the assistance of AI translation services.